You are using an outdated browser. For an optimal and safe experience we advise you to update your browser. Click here for the latest versions.

Programme

Preliminary programme: 

REGISTRATION 
09:30 – 10:00 Coffee and registration
   
OPENING & WELCOME
10:00 – 10:10 Welcome
  Prof. Sybe Schaap
   
SESSION 1: PLENARY SESSION - NOVEL DEVELOPMENTS
10:15-11:00 Opportunities and Challenges for RNA vaccines and therapeutics.
  Prof. Robin Shattock - Department of Infectious Disease, Imperial College London
11:00-11:45 Opportunities and Challenges for virus-based therapeutics in humans.
  Prof. Ron Fouchier - Department of Viroscience, Erasmus Medical Center
   
11:45 – 13:15 Lunch
   
SESSION 2: CLINICAL AND VETERINARY THERAPEUTICS
13:15- 13:45 First-in-human clinical trial with an alphavirus-based replicon vaccine against HPV-induced cancers.
  Prof. Toos Daemen - Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen
13:45 - 14:15 Vaccine platform technologies within Animal Health - Possibilities and limitations.
  Dr. Martijn Langereis - MSD Animal Health
   
SESSION 3: BIOSAFETY ASPECTS (working title)
14:15 - 14:45

Viral replicon systems and their biosafety aspects.

  Dr. Karen van der Meulen - Perseus
14:45 - 15:15 Rise of the RNA machines - self-amplification as next step in mRNA vaccine design.
  Dr. Gorben Pijlman - Laboratory of Virology, Wageningen University
   
15:15– 15:45 Coffee Break
   
SESSION 4: CONSIDERATIONS FOR REGULATION
15:45 - 16:05 Title tba.
  Dr. Marco Gielkens - GMO office, National Institute for Public Health and the Environment
16:05 - 17:15 Other speakers tba. Session includes discussion on future proof regulation
   
CONCLUDING REMARKS
17:15 - 17:25 Concluding remarks